Program Schedule

653
Implementation of PCV7/PCV13 in Israel Had a Significant Impact on both Pneumococcal and Non-Pneumococcal Complex Otitis Media (OM) Rates

Session: Poster Abstract Session: Adult and Pediatric Vaccines
Friday, October 10, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC
Posters
  • IDWeek 2014 Poster OM 1 oct.pdf (1.6 MB)
  • Background:  Pre-licensure and post implementation pneumococcal conjugate vaccine (PCV) studies have demonstrated that PCV impact on recurrent, non-responsive and chronic OM cases (complex-OM; COMP-OM) was significantly larger (up to 40%) than when all-cause OM or first OM were measured.  COMP-OM is frequently caused by non-pneumococcal pathogens, often forming biofilm, in which non-typable Haemophilus influenzae (NTHi) is the most frequent.  We assessed the impact of PCV7/PCV13 introduction on all-cause COMP-OM enriched OM episodes, as well as specifically pneumococcal, NTHi and culture-negative episodes.

     

    Methods: These were previously described (Dagan et al, 49th IDSA, Abstr. 1344, 2012). The surveillance period was Jul-2004 through Dec-2013.  PCV7 was introduced to the National Immunization Program (NIP; with catch-up) in Jul-2009 and has been gradually replaced by PCV13 since Nov-2010.

     

    Results: Overall, 6,250 OM episodes for which information was available, were submitted for culture.  ≥1 factors associated with COMP-OM were present in 2685/3996 (67%) children: 2165/3331 (65%) in culture-positive children and 520/665 (78%) in culture-negative patients.  Incidences (per 1,000 children <2 years) of PCV7+6A serotypes, serotypes 1, 3, 5, 7F, 19A, non-PCV13 serotypes and overall pneumococcal OM by 6 month-intervals and rate reduction calculations are shown in Figure 1.  Incidences of NTHi, culture-negative and all-cause OM as well as rate reduction calculations are shown in Figure 2.

     

    Conclusion: All OM cases, including pneumococcal, NTHi and culture-negative episodes enriched with COMP-OM were markedly reduced in children <2 years after PCV7/PCV13 introduction.

     

    Ron Dagan, MD1, Shalom Ben-Shimol, MD2, Eugene Leibovitz, MD2 and Noga Givon-Lavi, PhD1, (1)Pediatric Infectious Disease Unit, Ben-Gurion Univ of the Negev and Soroka Univ Med Ctr, Beer-Sheva, Israel, (2)Ben-Gurion Univ of the Negev and Soroka Univ Med Ctr, Beer-Sheva, Israel

    Disclosures:

    R. Dagan, Pfizer: Consultant, Grant Investigator, Scientific Advisor and Speaker's Bureau, Consulting fee, Research grant and Speaker honorarium
    MSD: Consultant, Grant Investigator and Scientific Advisor, Consulting fee and Research grant
    GSK: Consultant and Speaker's Bureau, Consulting fee and Speaker honorarium

    S. Ben-Shimol, None

    E. Leibovitz, Pfizer: Speaker's Bureau, Speaker honorarium

    N. Givon-Lavi, None

    Previous Abstract | Next Abstract >>

    Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

    Sponsoring Societies:

    © 2014, idweek.org. All Rights Reserved.

    Follow IDWeek